NEXAM CHEMICAL share 19/10 17:29
Price: 7.00  |   Change: -0.15 (-2.10%)


Anders Spetz, CEO

Tel: +46 (0)703-47 97 00

General Meetings of Shareholders

Under the provisions of the Swedish Companies Act, the General Meeting of Shareholders is the Company's highest decision-making body. At the General Meeting, shareholders exercise their right to vote on major decisions, for example, adoption of the income statement and balance sheets, distribution of the Company's profit, decision to discharge the Board members and the Managing Director from liability, election of Board members and auditors and decisions on remuneration to the members of the Board and the auditors.

As required by the Articles of Association, notification of an Annual General Meeting and an Extraordinary General Meeting must be published in the Swedish "Post- och Inrikes Tidningar" newspaper and on the Company's website. At the same time, a notice must be published in the Svenska Dagbladet newspaper that notification has been made.

Right to attend a General Meeting
All shareholders, who are directly entered in the share register held by Euroclear Sweden AB five business days before the General Meeting and who have notified the Company of their intention to attend (with any proxies) the General Meeting at the latest by the date and time indicated in the notice convening the Meeting, are entitled to attend the General Meeting and vote according to the number of shares they hold.

Shareholders may attend the General Meeting in person or be represented by proxy and may also be assisted by, at most, two persons. Shareholders are normally able to register for participation in the General Meeting in a number of ways, as indicated in the notice convening the Meeting.

Initiatives from shareholders
Shareholders who wish to propose a resolution at the General Meeting must submit a written request to the Board of Directors. In normal circumstances, the Board must have received the request no later than seven weeks before the General Meeting.

Nexam Chemical's Board of Directors has an authorisation to, on one or multiple occasions during the period leading up to the next annual general meeting, with or without deviation from the shareholders’ preferential rights, to resolve on new issues of shares. Issues may be made with or without the provisions regarding contribution in kind, setoff or other conditions. The number of shares that may be issued may not exceed a total of 12,944,000 shares (provided that such number of shares may be issued without amendment of the Articles of Association). The dilution may, upon full exercise of the authorization, amount to at the highest approximately 20 per cent. The purpose of the authorization is to enable to raise working capital, to enable to execute and finance acquisitions and to enable new issues to industrial partners within the framework of partnerships and alliances. To the extent the authorization is used for new issues with cash payment with deviation from the shareholders’ preferential rights, the issue price shall be on market terms.



© 2014, Nexam Chemical Holding AB (publ). Registered Office: Lund; Reg. No. 556919-9432